Publications by authors named "M E Holbein"
Objective: To assess knowledge and attitudes toward opioids and buprenorphine (BUP) of patients with cancer.
Design: Single-site, single-intervention telephone survey of patients under palliative care at the cancer center.
Outcomes: Forty percent of the participants recognized the word "buprenorphine," and 28 percent recognized BUP indication for addiction treatment.
Context: Stigma is known to impact the care of patients with opioid use disorder (OUD).
Objectives: This qualitative study seeks to understand how stigma is expressed in the medical chart by healthcare workers towards patients with cancer pain and OUD treated at an academic medical center.
Methods: This descriptive qualitative study utilized a thematic analysis approach to analyze the medical charts of 25 hospitalized patients with current or previous opioid use disorder and cancer with respect to their pain care in forty pain-related hospital admissions to a tertiary academic center from 2015 to 2020.
Article Synopsis
- The review is trying to understand what factors affect doctors' decisions when prescribing opioids to cancer patients who also have issues with substance misuse or addiction.
- Many cancer patients experience pain and often receive opioids, but doctors need to be careful because of the risks, especially for those with a history of substance problems.
- This review will look at studies that include adult cancer patients with substance use issues to find out how to manage their pain safely and effectively.
Background And Aims: Patients with severe alcohol-associated hepatitis (AH) have high mortality. Corticosteroids improve survival only for 30 days. We targeted inflammation, cellular injury, and gut leakiness in a randomized clinical trial comparing combination therapy to corticosteroids on 180-day survival.
View Article and Find Full Text PDFPurpose: The COVID-19 pandemic has led to profound changes in clinical research, including remote consent, telehealth, off-site procedures, shipment of therapy, and remote study monitoring. We assessed longitudinal perceptions of these adjustments among clinical research professionals.
Methods: We distributed an anonymous survey assessing experiences, perceptions, and recommendations regarding COVID-19-related clinical research adjustments to cancer clinical research office personnel in May 2020 and again in November 2020.